Analysis of ITGB1 expression in gastric cancer tissues and its impact on the efficacy of immunotherapy
10.13431/j.cnki.immunol.j.20240026
- VernacularTitle:ITGB1在胃癌组织中的表达及其对免疫治疗疗效的影响
- Author:
Hongyuan QIAO
1
;
Juan FU
;
Xincheng ZHAO
;
Yaqi PANG
Author Information
1. 443000 宜昌,三峡大学第二人民医院肿瘤放化疗科
- Keywords:
ITGB1;
Gastric adenocarcinoma;
Immunotherapy;
Bioinformatics methods
- From:
Immunological Journal
2024;40(2):188-194
- CountryChina
- Language:Chinese
-
Abstract:
The study aimed to investigate the expression of ITGB1 in gastric cancer tissues and its impact on the efficacy of immunotherapy,and to find a new biomarker for prognosis assessment and prediction of immunotherapy response in gastric cancer.By utilizing bioinformatics methods to analyze the transcriptomic data,clinical pathological characteristics,and survival information of gastric cancer patients in the Cancer Genome Atlas(TCGA)database,this study evaluates the expression of ITGB1 in gastric cancer and its correlation with clinical features.Furthermore,an in-depth analysis was conducted for evaluating the relationship of ITGB1 expression with immune infiltration,immune checkpoint-related genes,immune subtypes and immunotherapy response.Data showed that high ITGB1 expression in gastric cancer tissues is associated with later T stage,lower survival rates,and lower overall survival.Analysis of immune infiltration scores showed the score for CD4+T cells,CD8+T cells,neutrophils,macrophages and dendritic cells were higher in the high ITGB1 expression group.Additionally,the levels of immune checkpoint-related genes such as SIGLEC15,TIGIT,CD274,HAVCR2,CTLA4 and PDCD1LG2 were elevated in the high ITGB1 expression group,and the expression of ITGB1 was positively correlated with the expression of immune checkpoint-related genes including SIGLEC15,TIGIT,CD274,HAVCR2,CTLA4,LAG3 and PDCD1LG2.Analysis based on the data from the TISIDB database revealed differential expression of ITGB1 in various immune subtypes of gastric cancer,with significantly higher expression levels in the C6 subtype(TGF-β dominant type).The TIDE algorithm indicated a high score for the group with high ITGB1 expression,suggesting poor efficacy of immune checkpoint blockade therapy.To sum up,we find that high expression of ITGB1 in gastric cancer tissues is a poor prognostic indicator for gastric cancer patients,thus ITGB1 may serve as a potential biomarker for assessing prognosis and predicting the efficacy of immunotherapy in gastric cancer.
